27.46  -0.06 (-0.22%)		08-18 10:55
Open: 27.53 High: 27.61 Volume: 69,209		Pre. Close: 27.52 Low: 27.34 Market Cap: 1,810(M)

Short term
Mid term
Targets	6-month :	33.29	1-year :	35.33
Resists	First :	28.5	Second :	30.25
Pivot price	27.26
Supports	First :	25.68	Second :	21.36
MAs	MA(5) :	27.67	MA(20) :	27.49
	MA(100) :	28.47	MA(250) :	31.04
MACD	MACD :	-0.4	Signal :	-0.5
%K %D	K(14,3) :	55.5	D(3) :	61.8
RSI	RSI(14): 44.6
52-week	High :	37.77	Low :	25.68

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ LKFT ] has closed below upper band by 47.3%. Bollinger Bands are 5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	28.03 - 28.21	28.21 - 28.33
Low:	27.06 - 27.28	27.28 - 27.44
Close:	27.23 - 27.55	27.55 - 27.78

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

Fri, 14 Aug 2026
Lakefront Biotherapeutics NV: Target Price Consensus and Analysts Recommendations | LKFT | US36315X1019 - marketscreener.com

Thu, 13 Aug 2026
Broker Revenue Forecasts For Lakefront Biotherapeutics NV (AMS:LKFT) Are Surging Higher - simplywall.st

Wed, 12 Aug 2026
Lakefront Biotherapeutics (LKFT) repurchases 103,970 shares in €2.41M buyback tranche - Stock Titan

Wed, 12 Aug 2026
Acquisition of Own Shares - GlobeNewswire

Tue, 11 Aug 2026
Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln - marketscreener.com

Mon, 10 Aug 2026
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update - sg.finance.yahoo.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	65 (M)
Shares Float	485 (M)
Held by Insiders	25.3 (%)
Held by Institutions	22.6 (%)
Shares Short	2,320 (K)
Shares Short P.Month	2,180 (K)

EPS	8.56
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.8
Profit Margin	46.8 %
Operating Margin	-983 %
Return on Assets (ttm)	10.6 %
Return on Equity (ttm)	16.2 %
Qtrly Rev. Growth	-91.5 %
Gross Profit (p.s.)	10.92
Sales Per Share	15.88
EBITDA (p.s.)	10.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-302 (M)
Levered Free Cash Flow	211 (M)

PE Ratio	3.19
PEG Ratio	0
Price to Book value	9.72
Price to Sales	1.72
Price to Cash Flow	-5.94

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.